Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03464903 · ClinicalTrials.gov registry record
Study of ALS Reversals 2: Genetic Analyses
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 26
- Enrollment target
NCT03464903 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 26 participants.
The verdict
NCT03464903 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to try to understand why reversals of amyotrophic lateral sclerosis (ALS) and primary muscular atrophy (PMA) take place. The study will enroll patients with ALS or PMA reversals to give saliva samples in order to determine if the ALS or PMA reversal is because of certain changes in the genetic code.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-06-22 |
| Est. Completion | 2023-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03464903
The ClinicalTrials.gov registry entry for NCT03464903 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03464903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03464903 about?
NCT03464903 is a clinical study titled "Study of ALS Reversals 2: Genetic Analyses". The purpose of this study is to try to understand why reversals of amyotrophic lateral sclerosis (ALS) and primary muscular atrophy (PMA) take place. The study will enroll patients with ALS or PMA reversals to give saliva samples in order to determine if the ALS or PMA reversal is because of certain...
What is the current status of trial NCT03464903?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2018-06-22. Estimated completion is 2023-12-01.
Who is sponsoring clinical trial NCT03464903?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.